131 related articles for article (PubMed ID: 25239609)
1. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Guidetti A; Carlo-Stella C; Locatelli SL; Malorni W; Mortarini R; Viviani S; Russo D; Marchianò A; Sorasio R; Dodero A; Farina L; Giordano L; Di Nicola M; Anichini A; Corradini P; Gianni AM
Clin Cancer Res; 2014 Nov; 20(22):5641-51. PubMed ID: 25239609
[TBL] [Abstract][Full Text] [Related]
2. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC
J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396
[TBL] [Abstract][Full Text] [Related]
3. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
4. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of sorafenib in patients with relapsed or refractory lymphoma.
Guidetti A; Carlo-Stella C; Locatelli SL; Malorni W; Pierdominici M; Barbati C; Mortarini R; Devizzi L; Matteucci P; Marchianò A; Lanocita R; Farina L; Dodero A; Tarella C; Di Nicola M; Corradini P; Anichini A; Gianni AM
Br J Haematol; 2012 Jul; 158(1):108-19. PubMed ID: 22571717
[TBL] [Abstract][Full Text] [Related]
6. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
[TBL] [Abstract][Full Text] [Related]
8. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Grignani G; Palmerini E; Ferraresi V; D'Ambrosio L; Bertulli R; Asaftei SD; Tamburini A; Pignochino Y; Sangiolo D; Marchesi E; Capozzi F; Biagini R; Gambarotti M; Fagioli F; Casali PG; Picci P; Ferrari S; Aglietta M;
Lancet Oncol; 2015 Jan; 16(1):98-107. PubMed ID: 25498219
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.
Vincenzi B; Silletta M; Schiavon G; Frezza AM; Del Vescovo R; Zobel BB; Santini D; Dei Tos AP; Tonini G
Expert Opin Investig Drugs; 2013 Jan; 22(1):1-7. PubMed ID: 23157681
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Kim MN; Ro SW; Kim DY; Kim da Y; Cho KJ; Park JH; Lim HY; Han KH
Cancer Chemother Pharmacol; 2015 Aug; 76(2):257-67. PubMed ID: 26037205
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
Castellano D; Capdevila J; Sastre J; Alonso V; Llanos M; García-Carbonero R; Manzano Mozo JL; Sevilla I; Durán I; Salazar R
Eur J Cancer; 2013 Dec; 49(18):3780-7. PubMed ID: 24012098
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in patients with refractory or recurrent multiple myeloma.
Yordanova A; Hose D; Neben K; Witzens-Harig M; Gütgemann I; Raab MS; Moehler T; Goldschmidt H; Schmidt-Wolf IG
Hematol Oncol; 2013 Dec; 31(4):197-200. PubMed ID: 23494836
[TBL] [Abstract][Full Text] [Related]
15. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Gradishar WJ; Kaklamani V; Sahoo TP; Lokanatha D; Raina V; Bondarde S; Jain M; Ro SK; Lokker NA; Schwartzberg L
Eur J Cancer; 2013 Jan; 49(2):312-22. PubMed ID: 22954665
[TBL] [Abstract][Full Text] [Related]
17. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine.
Shome D; Trent J; Espandar L; Hatef E; Araujo DM; Song CD; Kim SK; Esmaeli B
Ophthalmology; 2008 Mar; 115(3):483-7. PubMed ID: 18201764
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.
Chen SW; Lin LC; Kuo YC; Liang JA; Kuo CC; Chiou JF
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1041-7. PubMed ID: 24661657
[TBL] [Abstract][Full Text] [Related]
19. Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.
Meyer A; Cygan P; Tolzien K; Galvez AG; Bitran JD; Lestingi TM; Nabhan C
Clin Genitourin Cancer; 2014 Apr; 12(2):100-5. PubMed ID: 24169494
[TBL] [Abstract][Full Text] [Related]
20. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
Bendell JC; Nemunaitis J; Vukelja SJ; Hagenstad C; Campos LT; Hermann RC; Sportelli P; Gardner L; Richards DA
J Clin Oncol; 2011 Nov; 29(33):4394-400. PubMed ID: 21969495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]